Welcome, Guest. Please login or register.
July 24, 2024, 08:06:23 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 225
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 41
Total: 41


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Entry Inhibitor Could Potentially Cure Hepatitis B and D  (Read 8056 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Entry Inhibitor Could Potentially Cure Hepatitis B and D
« on: August 07, 2019, 10:31:56 am »
Bulevirtide, formerly known as Myrcludex B, in combination with pegylated interferon, suppressed hepatitis delta virus (HDV) and led to a functional cure of hepatitis B virus (HBV) in some people living with HBV/HDV dual infection, according to a presentation at the 2019 International Liver Congress in Vienna.

HBV is difficult to treat in part because it produces cccDNA (covalently closed circular DNA), a genetic blueprint of the virus that can lie dormant in liver cells and evade both the immune system and standard therapy. Nucleoside/nucleotide antivirals such as Viread (tenofovir disiproxil fumarate), Vemlidy (tenofovir alafenamide) and Baraclude (entecavir) can suppress HBV replication long term during treatment, but they don’t eliminate the virus and usually do not lead to a cure, as indicated by hepatitis B surface antigen (HBsAg) loss and seroconversion.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.